MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,865,143
EPS
-$7.17
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
3,693,865
5,106,949
12,544,223.5*
3,161,064
Acquired in-process research and development expense
-
10,426,257
-
-
General and administrative
2,536,179
2,221,823
1,188,131*
1,400,136
Acquisition-related transaction costs
-
-
2,451,424.75*
-
Total general and administrative
-
-
3,639,555.75*
-
Sepa financing issuance costs
559,461
-
-
-
Total operating expenses
6,789,505
17,755,029
16,183,779.25
4,561,200
Operating loss
-6,789,505
-17,755,029
-16,183,779.25*
-4,561,200
Change in fair value of warrant liabilities
-229,221
125,348
7,436,948.5*
279,161
Change in fair value of contingent consideration
217,000
-116,000
-396,000*
-
Pipe warrant issuance costs
9,534
-
-
-
Grant income
21,316
139,835
1,014,078.5*
22,174
Currency exchange gain
-36,494
-21,108
7,242*
-32,051
Interest income
52,168
91,888
78,755.5*
147
Interest expense
-
-
-11,264*
5,960
Total other income (expense)
39,677
201,267
-5,929,608.5*
-294,851
Loss before income tax provision
-6,749,828
-17,553,762
-22,113,387.75*
-
Deferred income tax provision
300
231,309
56,517*
-
Net loss
-6,750,128
-17,785,071
-22,169,904.75*
-4,856,051
Accrual of paid-in-kind dividends on series a non-voting convertible preferred stock
115,015
1,725,225
402,552.75*
-
Net loss attributable to common stockholders
-6,865,143
-19,510,296
-22,572,457.5
-
Basic EPS
-7.17
-21.28
-56.178
-5.82
Diluted EPS
-7.17
-21.28
-56.178
-5.82
Basic Average Shares
957,191
916,968
401,802
833,683
Diluted Average Shares
957,191
916,968
401,802
833,683
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$6,865,143
(-60.53%↓ Y/Y)
Net loss
-$6,750,128
(-57.84%↓ Y/Y)
Accrual of paid-in-kind
dividends on series a...
$115,015
Change in fair value of
warrant liabilities
-$229,221
(-241.74%↓ Y/Y)
Interest income
$52,168
(35148.65%↑ Y/Y)
Grant income
$21,316
(-86.13%↓ Y/Y)
Loss before income
tax provision
-$6,749,828
Deferred income tax
provision
$300
Total other income
(expense)
$39,677
(171.66%↑ Y/Y)
Change in fair value of
contingent consideration
$217,000
Currency exchange gain
-$36,494
(23.15%↑ Y/Y)
Pipe warrant
issuance costs
$9,534
Operating loss
-$6,789,505
(-60.85%↓ Y/Y)
Total operating
expenses
$6,789,505
(60.85%↑ Y/Y)
Research and development
$3,693,865
(43.96%↑ Y/Y)
General and
administrative
$2,536,179
(53.23%↑ Y/Y)
Sepa financing
issuance costs
$559,461
Buy us a coffee
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)